Europe's drug regulator is putting a promising pancreatic cancer pill on the fast track. The European Medicines Agency (EMA) has launched a rolling review of daraxonrasib, Revolution Medicines' experimental treatment for previously treated metastatic pancreatic cancer. The move follows a late-stage trial showing the drug outperformed chemotherapy, and comes after the U.S. FDA already authorized early access to the pill in May 2026.
The European Medicines Agency (EMA) has kicked off a rolling review of daraxonrasib, Revolution Medicines' experimental oral treatment for metastatic pancreatic ductal adenocarcinoma (PDAC) — the most common and aggressive form of pancreatic cancer. The decision was triggered by results from a late-stage study showing daraxonrasib outperformed chemotherapy in patients whose disease had progressed after prior treatment.
The rolling review process allows the EMA's Committee for Medicinal Products for Human Use to assess quality, safety, and efficacy data as they become available — before a full marketing application is submitted — potentially shortening the overall timeline to approval. Daraxonrasib has also been designated a high-priority medicine under the EMA's Cancer Medicines Pathfinder program, reserved for treatments targeting significant unmet needs.
Key Takeaways:
Why it matters: Patients with previously treated metastatic pancreatic cancer face a grim outlook, with a median life expectancy of just six months and very few therapeutic options. With the U.S. FDA already granting early access in May 2026, regulatory momentum on both sides of the Atlantic signals real hope for a patient population that has long been underserved.
